Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) and Dermata Therapeutics (NASDAQ:DRMA – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.
Profitability
This table compares Pliant Therapeutics and Dermata Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pliant Therapeutics | N/A | -68.71% | -51.47% |
| Dermata Therapeutics | N/A | -191.95% | -140.15% |
Insider & Institutional Ownership
97.3% of Pliant Therapeutics shares are owned by institutional investors. Comparatively, 8.7% of Dermata Therapeutics shares are owned by institutional investors. 6.4% of Pliant Therapeutics shares are owned by insiders. Comparatively, 18.5% of Dermata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pliant Therapeutics | $1.58 million | 50.16 | -$149.34 million | ($2.44) | -0.52 |
| Dermata Therapeutics | N/A | N/A | -$12.29 million | ($7.81) | -0.20 |
Dermata Therapeutics has lower revenue, but higher earnings than Pliant Therapeutics. Pliant Therapeutics is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Pliant Therapeutics has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Comparatively, Dermata Therapeutics has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings for Pliant Therapeutics and Dermata Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pliant Therapeutics | 2 | 2 | 1 | 0 | 1.80 |
| Dermata Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
Pliant Therapeutics presently has a consensus target price of $3.00, suggesting a potential upside of 134.38%. Dermata Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 545.16%. Given Dermata Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Dermata Therapeutics is more favorable than Pliant Therapeutics.
Summary
Pliant Therapeutics beats Dermata Therapeutics on 6 of the 11 factors compared between the two stocks.
About Pliant Therapeutics
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
About Dermata Therapeutics
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Receive News & Ratings for Pliant Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pliant Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
